China Non-Hodgkin Lymphoma Therapeutics Market Report & Forecast 2021-2027

Publisher Name :
Date: 16-Nov-2021
No. of pages: 94
Inquire Before Buying

China Non-Hodgkin Lymphoma Therapeutics Market, By Type, 2016-2021, 2022-2027 ($ Millions)

China Non-Hodgkin Lymphoma Therapeutics Market Segment Percentages, By Type, 2020 (%)

- Chemotherapy

- Targeted Therapy

China Non-Hodgkin Lymphoma Therapeutics Market, By Application, 2016-2021, 2022-2027 ($ Millions)

China Non-Hodgkin Lymphoma Therapeutics Market Segment Percentages, By Application, 2020 (%)

- Clinical Research

- Treatment

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Non-Hodgkin Lymphoma Therapeutics revenues in China market, 2016-2021 (Estimated), ($ millions)

Key companies Non-Hodgkin Lymphoma Therapeutics revenues share in China market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

- Bristol Myers Squibb

- Celgene

- Eli Lilly

- F. Hoffman La-Roche

- GlaxoSmithKline

- Accredo Health Group

- Baxter International

- Bayer

- Cephalon

- Eisai Pharmaceuticals

China Non-Hodgkin Lymphoma Therapeutics Market Report & Forecast 2021-2027

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Non-Hodgkin Lymphoma Therapeutics Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China Non-Hodgkin Lymphoma Therapeutics Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 China Non-Hodgkin Lymphoma Therapeutics Overall Market Size
2.1 China Non-Hodgkin Lymphoma Therapeutics Market Size: 2021 VS 2027
2.2 China Non-Hodgkin Lymphoma Therapeutics Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Hodgkin Lymphoma Therapeutics Players in China Market
3.2 Top China Non-Hodgkin Lymphoma Therapeutics Companies Ranked by Revenue
3.3 China Non-Hodgkin Lymphoma Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Non-Hodgkin Lymphoma Therapeutics Companies in China Market, by Revenue in 2020
3.5 Companies Non-Hodgkin Lymphoma Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Hodgkin Lymphoma Therapeutics Players in China Market
3.6.1 List of Tier 1 Non-Hodgkin Lymphoma Therapeutics Companies in China
3.6.2 List of Tier 2 and Tier 3 Non-Hodgkin Lymphoma Therapeutics Companies in China
4 Sights by Type
4.1 Overview
4.1.1 By Type - China Non-Hodgkin Lymphoma Therapeutics Market Size Markets, 2021 & 2027
4.1.2 Chemotherapy
4.1.3 Targeted Therapy
4.2 By Type - China Non-Hodgkin Lymphoma Therapeutics Revenue & Forecasts
4.2.1 By Type - China Non-Hodgkin Lymphoma Therapeutics Revenue, 2016-2021
4.2.2 By Type - China Non-Hodgkin Lymphoma Therapeutics Revenue, 2022-2027
4.2.3 By Type - China Non-Hodgkin Lymphoma Therapeutics Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - China Non-Hodgkin Lymphoma Therapeutics Market Size, 2021 & 2027
5.1.2 Clinical Research
5.1.3 Treatment
5.2 By Application - China Non-Hodgkin Lymphoma Therapeutics Revenue & Forecasts
5.2.1 By Application - China Non-Hodgkin Lymphoma Therapeutics Revenue, 2016-2021
5.2.2 By Application - China Non-Hodgkin Lymphoma Therapeutics Revenue, 2022-2027
5.2.3 By Application - China Non-Hodgkin Lymphoma Therapeutics Revenue Market Share, 2016-2027
6 Non-Hodgkin Lymphoma Therapeutics Companies Profiles
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Company Details
6.1.2 Bristol Myers Squibb Business Overview
6.1.3 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Introduction
6.1.4 Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.1.5 Bristol Myers Squibb Recent Developments
6.2 Celgene
6.2.1 Celgene Company Details
6.2.2 Celgene Business Overview
6.2.3 Celgene Non-Hodgkin Lymphoma Therapeutics Introduction
6.2.4 Celgene Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.2.5 Celgene Recent Developments
6.3 Eli Lilly
6.3.1 Eli Lilly Company Details
6.3.2 Eli Lilly Business Overview
6.3.3 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Introduction
6.3.4 Eli Lilly Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.3.5 Eli Lilly Recent Developments
6.4 F. Hoffman La-Roche
6.4.1 F. Hoffman La-Roche Company Details
6.4.2 F. Hoffman La-Roche Business Overview
6.4.3 F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Introduction
6.4.4 F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.4.5 F. Hoffman La-Roche Recent Developments
6.5 GlaxoSmithKline
6.5.1 GlaxoSmithKline Company Details
6.5.2 GlaxoSmithKline Business Overview
6.5.3 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Introduction
6.5.4 GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.5.5 GlaxoSmithKline Recent Developments
6.6 Accredo Health Group
6.6.1 Accredo Health Group Company Details
6.6.2 Accredo Health Group Business Overview
6.6.3 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Introduction
6.6.4 Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.6.5 Accredo Health Group Recent Developments
6.7 Baxter International
6.7.1 Baxter International Company Details
6.7.2 Baxter International Business Overview
6.7.3 Baxter International Non-Hodgkin Lymphoma Therapeutics Introduction
6.7.4 Baxter International Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.7.5 Baxter International Recent Developments
6.8 Bayer
6.8.1 Bayer Company Details
6.8.2 Bayer Business Overview
6.8.3 Bayer Non-Hodgkin Lymphoma Therapeutics Introduction
6.8.4 Bayer Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.8.5 Bayer Recent Developments
6.9 Cephalon
6.9.1 Cephalon Company Details
6.9.2 Cephalon Business Overview
6.9.3 Cephalon Non-Hodgkin Lymphoma Therapeutics Introduction
6.9.4 Cephalon Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.9.5 Cephalon Recent Developments
6.10 Eisai Pharmaceuticals
6.10.1 Eisai Pharmaceuticals Company Details
6.10.2 Eisai Pharmaceuticals Business Overview
6.10.3 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Introduction
6.10.4 Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021)
6.10.5 Eisai Pharmaceuticals Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of Tables
Table 1. Non-Hodgkin Lymphoma Therapeutics Market Opportunities & Trends in China Market
Table 2. Non-Hodgkin Lymphoma Therapeutics Market Drivers in China Market
Table 3. Non-Hodgkin Lymphoma Therapeutics Market Restraints in China Market
Table 4. Key Players of Non-Hodgkin Lymphoma Therapeutics in China Market
Table 5. Top Non-Hodgkin Lymphoma Therapeutics Players in China Market, Ranking by Revenue (2019)
Table 6. China Non-Hodgkin Lymphoma Therapeutics Revenue by Companies, (US$, Mn), 2016-2021
Table 7. China Non-Hodgkin Lymphoma Therapeutics Revenue Share by Companies, 2016-2021
Table 8. Companies Non-Hodgkin Lymphoma Therapeutics Product Type
Table 9. List of Tier 1 Non-Hodgkin Lymphoma Therapeutics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Non-Hodgkin Lymphoma Therapeutics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - China Non-Hodgkin Lymphoma Therapeutics Revenue, (US$, Mn), 2021 & 2027
Table 12. By Type - China Non-Hodgkin Lymphoma Therapeutics Revenue (US$, Mn), 2016-2021
Table 13. By Type - China Non-Hodgkin Lymphoma Therapeutics Revenue (US$, Mn), 2022-2027
Table 14. By Application - China Non-Hodgkin Lymphoma Therapeutics Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - China Non-Hodgkin Lymphoma Therapeutics Revenue (US$, Mn), 2016-2021
Table 16. By Application - China Non-Hodgkin Lymphoma Therapeutics Revenue (US$, Mn), 2022-2027
Table 17. Bristol Myers Squibb Company Details
Table 18. Bristol Myers Squibb Business Overview
Table 19. Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Product
Table 20. Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 21. Bristol Myers Squibb Recent Developments
Table 22. Celgene Company Details
Table 23. Celgene Business Overview
Table 24. Celgene Non-Hodgkin Lymphoma Therapeutics Product
Table 25. Celgene Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 26. Celgene Recent Developments
Table 27. Eli Lilly Company Details
Table 28. Eli Lilly Business Overview
Table 29. Eli Lilly Non-Hodgkin Lymphoma Therapeutics Product
Table 30. Eli Lilly Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 31. Eli Lilly Recent Developments
Table 32. F. Hoffman La-Roche Company Details
Table 33. F. Hoffman La-Roche Business Overview
Table 34. F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Product
Table 35. F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 36. F. Hoffman La-Roche Recent Developments
Table 37. GlaxoSmithKline Company Details
Table 38. GlaxoSmithKline Business Overview
Table 39. GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Product
Table 40. GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 41. GlaxoSmithKline Recent Developments
Table 42. Accredo Health Group Company Details
Table 43. Accredo Health Group Business Overview
Table 44. Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Product
Table 45. Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 46. Accredo Health Group Recent Developments
Table 47. Baxter International Company Details
Table 48. Baxter International Business Overview
Table 49. Baxter International Non-Hodgkin Lymphoma Therapeutics Product
Table 50. Baxter International Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 51. Baxter International Recent Developments
Table 52. Bayer Company Details
Table 53. Bayer Business Overview
Table 54. Bayer Non-Hodgkin Lymphoma Therapeutics Product
Table 55. Bayer Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 56. Bayer Recent Developments
Table 57. Cephalon Company Details
Table 58. Cephalon Business Overview
Table 59. Cephalon Non-Hodgkin Lymphoma Therapeutics Product
Table 60. Cephalon Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 61. Cephalon Recent Developments
Table 62. Eisai Pharmaceuticals Company Details
Table 63. Eisai Pharmaceuticals Business Overview
Table 64. Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Product
Table 65. Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Revenue in China Market (2016-2021) & (US$ Million)
Table 66. Eisai Pharmaceuticals Recent Developments
List of Figures
Figure 1. Non-Hodgkin Lymphoma Therapeutics Segment by Type
Figure 2. Non-Hodgkin Lymphoma Therapeutics Segment by Application
Figure 3. China Non-Hodgkin Lymphoma Therapeutics Market Overview: 2020
Figure 4. China Non-Hodgkin Lymphoma Therapeutics Market Size: 2021 VS 2027 (US$, Mn)
Figure 5. China Non-Hodgkin Lymphoma Therapeutics Revenue, 2016-2027 (US$, Mn)
Figure 6. The Top 3 and 5 Players Market Share by Non-Hodgkin Lymphoma Therapeutics Revenue in 2020
Figure 7. By Type - China Non-Hodgkin Lymphoma Therapeutics Revenue Market Share, 2016-2027
Figure 8. By Application - China Non-Hodgkin Lymphoma Therapeutics Revenue Market Share, 2016-2027
Figure 9. Bristol Myers Squibb Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 10. Celgene Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 11. Eli Lilly Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 12. F. Hoffman La-Roche Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 13. GlaxoSmithKline Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 14. Accredo Health Group Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 15. Baxter International Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 16. Bayer Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 17. Cephalon Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 18. Eisai Pharmaceuticals Non-Hodgkin Lymphoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
  • Global Cancer Immunomodulator Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
  • Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
  • Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 125
    According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period. Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
  • Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 112
    This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
  • Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Gene Therapy market: According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
  • T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 85
    CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
  • Global Kaposi Sarcoma Market Status and Outlook 2023-2028
    Published: 22-Dec-2023        Price: US 3160 Onwards        Pages: 107
    Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
  • Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Cancer Immunomodulator market: According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs